Randomized Phase II of Lomustine Versus Lomustine-Dasatinib in Patients With Recurrent Glioblastoma.

Trial Profile

Randomized Phase II of Lomustine Versus Lomustine-Dasatinib in Patients With Recurrent Glioblastoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2014

At a glance

  • Drugs Dasatinib (Primary) ; Lomustine
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Jun 2012 Planned number of patients changed from 108 to 120 as reported by EudraCT.
    • 26 Jul 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 06 Jul 2011 Planned end date changed from Dec 2011 to May 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top